Ongoing phase 3 trials are investigating coinhibitory targets such as TIGIT, VISTA, LAG3, TIM3, and Siglec-15, where tiragolumab (anti-TIGIT) combined with atezolizumab (anti–PD-L1) has demonstrated increased overall response rate and progression-free survival in PD-L1-positive NSCLC patients [28,102]. The gene discussed is TIGIT; the disease is non-small cell lung carcinoma.